AKT1 and lung carcinoma: Akt and mTOR targeted drugs were developed for cancer treatment [24]. Therefore, the compounds with an ability to induce apoptosis and autophagy by inhibiting PI3K/Akt/mTOR pathway are of interest as good candidates for lung cancer therapy.